ABK Biomedical, Inc. announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers. This study is being conducted in collaboration with Auckland Hospital Research Unit, New Zealand. The prospective, single-center, open-label study is evaluating the safety and effectiveness of Eye90 microspheres in patients…
eTurboNews články sú len pre predplatiteľov. Predplatné je ZADARMO.
Odberatelia sa prihlasujú tu Kliknite sem a prihláste sa na odber ZDARMA
Odberatelia sa prihlasujú tu Kliknite sem a prihláste sa na odber ZDARMA
ČO SI Z TOHTO ČLÁNKU ODniesť:
- oznámila prvého pacienta liečeného v štúdii ABK First-in-Human pomocou Eye90 microspheres™, rádioembolizačného zariadenia Y90 na liečbu rakoviny pečene.
- This study is being conducted in collaboration with Auckland Hospital Research Unit, New Zealand.
- The prospective, single-center, open-label study is evaluating the safety and effectiveness of Eye90 microspheres in patients….
